tiprankstipranks
Teleflex Inc (TFX)
NYSE:TFX
Want to see TFX full AI Analyst Report?

Teleflex (TFX) Price & Analysis

450 Followers

TFX Stock Chart & Stats

$138.74
$0.94(0.72%)
At close: 4:00 PM EDT
$138.74
$0.94(0.72%)

Bulls Say, Bears Say

Bulls Say
Recurring Procedure-driven DemandTeleflex benefits from repeat purchasing of single-use and procedure-oriented devices used in routine and acute hospital care. This consumable-led model can support durable revenue visibility, while direct clinical selling and distribution broaden access across healthcare systems and geographies.
Deleveraging After OEM DivestitureThe OEM divestiture has converted a non-core asset into substantial cash for debt reduction, lowering pro forma leverage and expected interest expense. Greater balance-sheet flexibility should improve resilience and leave more capacity to fund strategic investment and shareholder returns over the next several quarters.
Innovation Pipeline And Product DevelopmentElevated R&D investment and regulatory and clinical progress expand Teleflex’s opportunity set in emergency medicine and interventional therapies. Approved and advancing platforms can strengthen differentiation, support future adoption, and reduce reliance on mature product categories as development milestones translate into commercialization.
Bears Say
Severe Profitability DeteriorationThe shift from historically healthy profitability to a large TTM net loss is a major fundamental weakness. Even with solid gross margin, weak operating earnings reduce internal funding capacity, limit financial flexibility, and make sustained earnings recovery dependent on successful cost and portfolio actions.
Higher Leverage And Weaker CoverageHigher leverage combined with deeply negative returns increases the financial burden on a business already experiencing earnings pressure. Although equity remains sizable, weaker obligation coverage reduces room to absorb execution setbacks and may constrain capital allocation until debt reduction and profitability improvement are delivered.
Integration Is Limiting Growth And MarginsThe prolonged VI integration is affecting order-to-cash processes, distributor transitions, and sales-force alignment, creating a durable execution overhang. The resulting Interventional weakness has lowered company growth expectations and may continue delaying operating leverage and margin normalization through 2026.

Teleflex News

TFX FAQ

What was Teleflex Inc’s price range in the past 12 months?
Teleflex Inc lowest stock price was $100.18 and its highest was $145.00 in the past 12 months.
    What is Teleflex Inc’s market cap?
    Teleflex Inc’s market cap is $5.75B.
      When is Teleflex Inc’s upcoming earnings report date?
      Teleflex Inc’s upcoming earnings report date is Oct 22, 2026 which is in 41 days.
        How were Teleflex Inc’s earnings last quarter?
        Teleflex Inc released its earnings results on Aug 06, 2026. The company reported $1.76 earnings per share for the quarter, beating the consensus estimate of $1.281 by $0.479.
          Is Teleflex Inc overvalued?
          According to Wall Street analysts Teleflex Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
            Does Teleflex Inc pay dividends?
            Teleflex Inc pays a Quarterly dividend of $0.34 which represents an annual dividend yield of 1.03%. See more information on Teleflex Inc dividends here
              What is Teleflex Inc’s EPS estimate?
              Teleflex Inc’s EPS estimate is 1.9.
                How many shares outstanding does Teleflex Inc have?
                Teleflex Inc has 42,372,400 shares outstanding.
                  What happened to Teleflex Inc’s price movement after its last earnings report?
                  Teleflex Inc reported an EPS of $1.76 in its last earnings report, beating expectations of $1.281. Following the earnings report the stock price went up 1.543%.
                    Which hedge fund is a major shareholder of Teleflex Inc?
                    Currently, no hedge funds are holding shares in TFX
                    What is the TipRanks Smart Score and how is it calculated?
                    Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                      Company Description

                      Teleflex Inc

                      Teleflex Incorporated is a global medical technology company dedicated to designing, developing, manufacturing, and distributing single-use medical devices. These products are crucial for diagnostic and therapeutic procedures, particularly within critical care and surgical environments worldwide. Its comprehensive product portfolio includes: Vascular Access Solutions: Featuring the "Arrow" brand, these include catheters, advanced catheter navigation and tip positioning systems, and intraosseous access systems. They are essential for administering intravenous therapies, monitoring blood pressure, and drawing blood samples, all achievable through a single access point. Interventional Cardiology & Radiology Products: This segment covers various coronary catheters, therapies for structural heart conditions, and devices for peripheral intervention and cardiac assist. Key users include interventional cardiologists, radiologists, and vascular surgeons. Specific offerings comprise Arrow, Guideline, and Trapliner catheters, the Manta Vascular Closure Device, and Arrow Oncontrol systems. Anesthesia and Surgical Products: The company provides anesthesia and pain management products, serving hospitals, emergency medical services, and military health organizations. Its surgical division offers metal and polymer ligation clips, fascial closure systems for laparoscopic procedures, percutaneous surgical systems, and a range of other surgical instruments. Interventional Urology & General Urology: Teleflex's interventional urology offerings prominently feature the UroLift System, an innovative treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH). Additionally, it supplies general urology products like catheters, urine collection devices, catheterization accessories, and tools for operative endourology, alongside providing bladder management services. Respiratory Care Products: This category includes oxygen and aerosol therapy devices, spirometry equipment, and ventilation management systems, applicable across diverse healthcare settings. Teleflex serves a broad customer base, encompassing hospitals, healthcare providers, medical device manufacturers, and the home care market. Established in 1943, the company maintains its headquarters in Wayne, Pennsylvania.

                      Teleflex (TFX) Earnings & Revenues

                      TFX Company Deck

                      TFX Earnings Call

                      Q2 2026
                      0:00 / 0:00
                      Earnings Call Sentiment|Positive
                      The call presents a cautiously optimistic outlook: management reported a quarter that beat on revenue, margin and EPS expectations, closed a sizable OEM divestiture generating ~$1.5B of proceeds to accelerate debt paydown and share repurchases, and highlighted meaningful innovation and R&D progress (EZPLAZ approval, Freesolve milestones). However, the company is navigating near-term headwinds — primarily slower-than-expected integration of the VI acquisition that pressured Interventional revenue, margin compression from tariffs and acquisition mix, stranded costs and regulatory timing on remaining divestitures. Management reiterated a clear plan to reduce debt, return capital, increase R&D focus and deliver margin improvement in 2027, and raised FY EPS guidance while trimming FY revenue growth guidance. On balance, the positive strategic moves, capital returns and innovation progress outweigh the transient integration and margin challenges, with improved financial profile expected in 2027.View all TFX earnings summaries

                      TFX Stock 12 Month Forecast

                      Average Price Target

                      $157.63
                      ▲(13.61% Upside)
                      {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"101":"$101","136":"$136","171":"$171","118.5":"$118.5","153.5":"$153.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":170,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$170.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":157.625,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$157.63</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":145,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$145.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[101,118.5,136,153.5,171],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,140.48,142.7507692307692,145.02153846153846,147.29230769230767,149.56307692307692,151.83384615384614,154.10461538461539,156.3753846153846,158.64615384615385,160.91692307692307,163.18769230769232,165.45846153846153,167.72923076923078,{"y":170,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,140.48,141.79884615384614,143.1176923076923,144.43653846153845,145.7553846153846,147.07423076923075,148.3930769230769,149.71192307692309,151.03076923076924,152.3496153846154,153.66846153846154,154.9873076923077,156.30615384615385,{"y":157.625,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,140.48,140.8276923076923,141.17538461538462,141.52307692307693,141.8707692307692,142.21846153846153,142.56615384615384,142.91384615384615,143.26153846153846,143.60923076923078,143.95692307692306,144.30461538461537,144.6523076923077,{"y":145,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":125.018,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":122.556,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":123.1,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":113.503,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":121.072,"date":1767225600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":102.541,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":121.955,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":117.822,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":121.155,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":127.254,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":129.428,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":136.371,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":140.48,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                      Similar Stocks
                      Company
                      Price & Change
                      Follow
                      AngioDynamics
                      Baxter International
                      Becton Dickinson
                      ICU Medical
                      Merit Medical Systems

                      Ownership Overview

                      0.44%36.72%17.01%22.26%
                      17.01% Other Institutional Investors
                      22.26% Public Companies and
                      Individual Investors
                      Popular Stocks